Diabetic nephropathy: How might we prevent, retard, or cope with it

Australian Family Physician

Volumn 34, Issue 11, 2005, Pages 933-936

  Nicholls, Kathy ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ALBUMINURIA; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENERAL PRACTICE; HUMAN; HYPERTENSION; METHODOLOGY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTEIN INTAKE; REVIEW; URINE;

ALBUMINURIA; CREATININE; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIETARY PROTEINS; FAMILY PRACTICE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; PRIMARY PREVENTION;

EID: 33644833918     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (29)

1. Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-72.
2. Bo-abbas YY, Brousseau VJ, Louria DB, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
3. Padwal R, Majumdar SR, Johnson JA, Janice Varney, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28:736-44.
4. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004;22:1845-7.
5. Opie LH. Old antihypertensives and new diabetes. J Hypertens 2004;22:1453-8.
6. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-74.
7. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983;32:106-11.
8. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999;33:1130-4.
9. Eberly LE, Cohen JD, Prineas R, Yang L. Intervention trial research group. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18 year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003;26:848-54.
10. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
11. Shamiss A, Carrol J, Peleg E, Grossman E, Rosenthal T. Enalapril with and without hydrochlorothiazide: effects on insulin sensitivity and metabolic abnormalities of NIDDM hypertensive patients. Am J Hypertens 1995;8:276-81.
12. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
14. The Diabetes Control and Complications Trial Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
15. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, 2002.
16. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS. Lancet 1998;352:837-53.
17. Chase HP, Garg SK, Marshall G, et al. Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA 1991;265:614-7.
18. Chuahirun T, Wesson DE. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis 2002;39:376-82.
19. Kasiske BL, Kalil RS, Ma JZ, Liao M, Kean WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta regression analysis. Ann Intern Med 1993;118:129-38.
20. Lovell HG for Cochrane Diabetes Group. Are angiotensive converting enzyme inhibitors useful for normotensive diabetic patients with microalbuminuria? Cochrane Database of Systematic Reviews. Issue 2. Oxford: Update Software, 2000.
21. Waugh and Robertson for the Cochrane Diabetes Group. Cochrane Database of Systematic Reviews Vol 1, 2000.
22. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
23. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
24. Lewis EJ, Hunsickeler LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 Diabetes. N Engl J Med 2001;345:851-60.
25. Barnett A, Bain S, Bouter P, et al. Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2001;351:1952-61.
26. Lacourciere Y, Belanger A, Godin C, et al. Long term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9.
27. Deferrari G, Ravera M, Beruti V, Leoncini G, Deferrari L. Optimising therapy in the diabetic patient with renal disease: antihypertensive therapy. J Am Soc Nephrol 2004;15(Suppl 1):S6-11.
28. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-65.
29. JNC VII Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-71.